©The Author(s) 2017.
World J Hepatol. Sep 18, 2017; 9(26): 1092-1100
Published online Sep 18, 2017. doi: 10.4254/wjh.v9.i26.1092
Published online Sep 18, 2017. doi: 10.4254/wjh.v9.i26.1092
Table 1 Management of suspected methotrexate toxicity
| Transaminase monitoring | Commencing | Every 2 wk |
| Adjusting dose | Every 2 wk | |
| Stable dose | Every 12 wk | |
| Elevated transaminases | New persistent elevation | Reduce methotrexate, investigate |
| New elevation greater than 3 times upper limit normal | Withdraw methotrexate, investigate, methotrexate may be restarted after normalisation | |
| Liver biopsy | Indication | Investigation of other potential causes of elevated transaminases |
| Very rarely for confirmation of methotrexate induced toxicity |
- Citation: Conway R, Carey JJ. Risk of liver disease in methotrexate treated patients. World J Hepatol 2017; 9(26): 1092-1100
- URL: https://www.wjgnet.com/1948-5182/full/v9/i26/1092.htm
- DOI: https://dx.doi.org/10.4254/wjh.v9.i26.1092